16.01
전일 마감가:
$15.93
열려 있는:
$15.81
하루 거래량:
1.51M
Relative Volume:
0.67
시가총액:
$2.44B
수익:
$205.22M
순이익/손실:
$-121.24M
주가수익비율:
-19.67
EPS:
-0.8141
순현금흐름:
$-82.81M
1주 성능:
+1.70%
1개월 성능:
+16.76%
6개월 성능:
+57.87%
1년 성능:
+145.52%
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
명칭
Adaptive Biotechnologies Corp
전화
206-659-0067
주소
1165 EASTLAKE AVE E, SEATTLE, WA
ADPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ADPT
Adaptive Biotechnologies Corp
|
16.00 | 2.43B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.82 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
869.11 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.76 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.74 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-09-30 | 개시 | Guggenheim | Buy |
| 2025-06-18 | 개시 | Craig Hallum | Buy |
| 2025-03-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-12-21 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Underperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2022-02-16 | 재확인 | BTIG Research | Buy |
| 2022-02-16 | 재확인 | BofA Securities | Buy |
| 2022-02-16 | 재확인 | Goldman | Neutral |
| 2022-02-16 | 재확인 | JP Morgan | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-03-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-03 | 개시 | Goldman | Buy |
| 2019-07-23 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | BofA/Merrill | Buy |
| 2019-07-22 | 개시 | Cowen | Outperform |
| 2019-07-22 | 개시 | Goldman | Neutral |
| 2019-07-22 | 개시 | Guggenheim | Buy |
| 2019-07-22 | 개시 | William Blair | Outperform |
모두보기
Adaptive Biotechnologies Corp 주식(ADPT)의 최신 뉴스
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M - Investing.com
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst - Benzinga
Adaptive Biotechnologies inks two agreements with Pfizer in immunology - Investing.com India
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M By Investing.com - Investing.com South Africa
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Yahoo Finance
Adaptive (NASDAQ: ADPT) signs RA TCR, data licensing pacts with Pfizer (NYSE: PFE) - Stock Titan
How Investors Are Reacting To Adaptive Biotechnologies (ADPT) clonoSEQ Data Shaping MRD-Guided Cancer Care - Yahoo Finance
Insider Sell: Robert Hershberg Sells 22,968 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
Adaptive Biotechnologies Director Sells Shares - TradingView — Track All Markets
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Dir Hershberg Files To Sell 22,968 Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
Take off with Adaptive Biotechnologies Corp (ADPT): Get ready for trading - setenews.com
Adaptive Biotechnologies to Discuss clonoSEQ Technology and Minimal Residual Disease at Jefferies Fireside Chat - Quiver Quantitative
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - Yahoo Finance
Adaptive Biotechnologies chief commercial officer sells $212k in stock - Investing.com
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake - Insider Monkey
Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares - StocksToTrade
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at ASH Meeting - GuruFocus
Adaptive Biotechnologies Stock Declines After Insider Sale - timothysykes.com
December Disappointments: 10 Big Names Troubled Early - Insider Monkey
Seattle InnoLayoffs at Adaptive I Rover's marketing efforts - The Business Journals
Adaptive Biotechnologies’ Stock Faces Turmoil Amid Insider Selling - StocksToTrade
Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting - marketscreener.com
Adaptive Biotechnologies Highlights Expanded Clinical Use of clonoSEQ® Test at 67th ASH Annual Meeting - Quiver Quantitative
Adaptive Biotechnologies (Nasdaq: ADPT) shows clonoSEQ MRD guiding blood cancer care at ASH 2025 - Stock Titan
Insider Sell: Harlan Robins Sells 37,212 Shares of Adaptive Biot - GuruFocus
Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock - Investing.com
Adaptive Biotechnologies Exec Sells Over $670K in Company Stock - TradingView
Officer Robins Sells 37,212 ($672.5K) Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Adaptive Biotechnologies (ADPT) Is Down 11.2% After Earnings Beat And CFO Share SaleHas The Bull Case Changed? - simplywall.st
Will Adaptive Biotechnologies Corporation stock beat EPS estimatesDollar Strength & AI Enhanced Trading Alerts - Newser
Officer Robins Files To Sell 10,000 Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
Will Adaptive Biotechnologies Corporation (1HM) stock draw ESG focused funds2025 Earnings Surprises & Stock Portfolio Risk Control - Newser
Will Adaptive Biotechnologies Corporation (1HM) stock sustain uptrend momentum2025 Dividend Review & Real-Time Volume Analysis Alerts - Newser
Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback - Yahoo Finance
Ready to Jump After Recent Trade: Adaptive Biotechnologies Corp (ADPT) - setenews.com
Adaptive biotechnologies CFO Piskel sells $3.17 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $2,367,462.12 in Stock - MarketBeat
ADPT FinancialsIncome Statement - Quiver Quantitative
Adaptive biotechnologies CFO Piskel sells $3.17 million in stock - Investing.com
Adaptive Biotechnologies CFO Kyle Piskel Sells Over 162K Shares - TradingView — Track All Markets
CFO Piskel Sells 162,820 ($3.2M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Adaptive Biotechnologies (ADPT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ameritas Investment Partners Inc. Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - Defense World
Chad Robins Sells 160,734 Shares of Adaptive Biotechnologies Cor - GuruFocus
Adaptive Biotechnologies CEO Robins sells $3.07 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CEO Robins sells $3.07 million in stock - Investing.com
Adaptive Biotechnologies CEO Sells Shares Worth Over $3 Million - TradingView — Track All Markets
Adaptive Biotechnologies Corp (ADPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Adaptive Biotechnologies Corp 주식 (ADPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HERSHBERG ROBERT | Director |
Dec 10 '25 |
Sale |
16.00 |
22,968 |
367,488 |
46,722 |
자본화:
|
볼륨(24시간):